KOSDAQ · 141080.KQ · 리가켐바이오

LigaChem Biosciences

59,300 won+4.40%KRX close 2026-11-10

One year, weekly closes

52-week high: 225,000
52-week low: 54,100
Year to date: -65.9%

Broker consensus

210,000 won average target

2 brokerages · median 210,000 · range 200,000–220,000 · average target +254.1% vs last close

Ratings: Buy 2

Latest target from each brokerage in the past 180 days. Targets and ratings are the brokerages' own; Seoul Market Wire publishes none.

Price-target history

Date	Brokerage	Rating	Target (won)	Previous	Change	Report
2026-08-05	Hana Securities	Buy	220,000	—	—	Korean
2026-05-21	iM Securities	Buy	200,000	—	—	Korean

Korean brokerage reports since 2026-04-22, newest first. Change is against the same brokerage's previous target. Source: reports listed on Naver Pay Securities research. Updated 2026-11-10 20:21 KST.

Investor flows, last 20 sessions

Date	Foreign, shares	Foreign, approx. won	Institutions, approx. won	Foreign ownership
2026-11-10	23,122	+₩1.4bn	−₩0.7bn	14.26%
2026-11-09	66,539	+₩3.7bn	−₩4.0bn	14.20%
2026-11-06	-77,449	−₩4.6bn	+₩4.1bn	14.01%
2026-11-05	-40,489	−₩2.6bn	+₩5.0bn	14.22%
2026-11-04	29,913	+₩1.8bn	−₩1.9bn	14.44%
2026-11-03	47,539	+₩2.9bn	−₩2.7bn	14.42%
2026-11-02	13,794	+₩0.9bn	−₩0.8bn	14.30%
2026-10-30	37,637	+₩2.3bn	−₩1.5bn	14.27%
2026-10-29	83,127	+₩5.3bn	−₩5.7bn	14.14%
2026-10-28	74,497	+₩4.9bn	−₩4.9bn	13.91%
2026-10-27	10,840	+₩0.7bn	−₩1.9bn	13.69%
2026-10-26	54,562	+₩3.5bn	−₩4.0bn	13.65%
2026-10-23	39,069	+₩2.7bn	−₩2.4bn	13.50%
2026-10-22	34,277	+₩2.4bn	−₩1.8bn	13.39%
2026-10-21	1,060	+₩0.1bn	−₩1.3bn	13.28%
2026-10-20	16,272	+₩1.1bn	−₩0.1bn	13.26%
2026-10-19	40,557	+₩2.9bn	−₩1.7bn	13.22%
2026-10-16	48,826	+₩3.3bn	+₩0.7bn	13.14%
2026-10-15	29,149	+₩1.8bn	+₩1.2bn	12.97%
2026-10-14	30,718	+₩2.0bn	−₩1.9bn	12.88%

Net buying (+) or selling (−) by foreign investors and institutions. Won values are shares × that day's close, so approximate. Source: Korea Exchange data via Naver Pay Securities.

Stories

No stories on LigaChem Biosciences yet.

For information only. Not investment advice. See our disclaimer.